Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.40 and traded as low as $4.39. Minerva Neurosciences shares last traded at $4.69, with a volume of 151,122 shares traded.
Wall Street Analysts Forecast Growth
NERV has been the subject of several research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Minerva Neurosciences in a research note on Wednesday, June 24th. Jefferies Financial Group raised shares of Minerva Neurosciences from a "hold" rating to a "mixed" rating and raised their target price for the stock from $7.50 to $10.00 in a research note on Friday, August 14th. Zacks Research cut Minerva Neurosciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, August 12th. Finally, Wall Street Zen upgraded Minerva Neurosciences from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Minerva Neurosciences currently has an average rating of "Reduce" and a consensus price target of $10.33.
Get Our Latest Stock Report on NERV
Minerva Neurosciences Trading Up 4.7%
The firm has a fifty day moving average price of $4.54 and a 200 day moving average price of $5.40. The firm has a market cap of $223.95 million, a PE ratio of -0.16 and a beta of -0.08.
Minerva Neurosciences (NASDAQ:NERV - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. As a group, equities analysts predict that Minerva Neurosciences, Inc will post -0.73 earnings per share for the current year.
Institutional Trading of Minerva Neurosciences
Hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC purchased a new stake in shares of Minerva Neurosciences during the 4th quarter valued at approximately $36,000. OMERS ADMINISTRATION Corp purchased a new position in Minerva Neurosciences in the first quarter worth approximately $62,000. Cannon Global Investment Management LLC acquired a new stake in Minerva Neurosciences during the first quarter worth $107,000. State Street Corp raised its position in Minerva Neurosciences by 45.4% in the fourth quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 7,500 shares during the period. Finally, Bank of America Corp DE raised its position in Minerva Neurosciences by 78,272.5% in the first quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company's stock valued at $241,000 after purchasing an additional 39,919 shares during the period. Institutional investors and hedge funds own 34.56% of the company's stock.
Minerva Neurosciences Company Profile
(
Get Free Report)
Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company's research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva's goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.
The company's most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Minerva Neurosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Minerva Neurosciences wasn't on the list.
While Minerva Neurosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
